17 April 2014

Plethora treatment wins NHS approval

15/04/2011 Ben Jaglom

Specialist pharmaceutical concern Plethora Solutions Holdings (PLE) says it has won approval for its vaginal dryness treatment Hyalofemme from the NHS for prescription.

The agreement means that doctors in the UK will now be able to write prescriptions for Hyalofemme for the first time for atrophic vaginitis, commonly referred to as vaginal dryness. Traditional treatments involve the use of hormonal creams containing estrogen, but such creams are often inappropriate for cancer patients, who often suffer vaginal dryness as a side effect of cancer treatment.

Chairman Bill Robinson remarks the decision by the NHS should 'increase the commercial value of our pipeline by exploiting products secured last year'. He adds that the release of Hyalofemme is an 'important treatment' for atrophic vaginitis.

Following the announcement analysts at house broker Daniel Stewart held their forecasts of a year-end loss of £1.3 million (2010: loss of £1.5 million) on revenue up £100,000 to £1.2 million. They have pencilled in a loss per share of 2.5p for 2011 and a further loss of 3.4p a share for 2012.

Shares in Plethora were up 0.25p this morning following the announcement to 7.5p, the price at which Growth Company Investor recommended them earlier this month. A good sign for the company's prospects, Hyalofemme will be prescribed both for those being treated for cancer and women going through the menopause. We therefore reiterate our speculative buy rating.

Tags: AIM market, Menopause, Pharma, Plethora Solutions Holdings, Urology Company, Vaginal dryness

The Share Centre:

Cheaper fund investing has arrived at The Share Centre.
We don't believe it's fair to charge you extra just for holding funds.
So we don't. Find out more.
Capital at risk.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2014

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1,044 AIM-quoted companies. The full report is available to order for £365 + VAT. Click here for more info

Cash Shells 2013

This annual guide provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. The guide is available to order in PDF format for £350 (+VAT). More info

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

RPC is an environmental consultancy

RPS gets clear 10/04/2014

Environmental specialist RPS Group (LSE:RPC) has purchased Clear Environmental Consultants in a deal worth £8.3 million.

Tags: Clean energy

Motive moving on tablet 10/04/2014

Television technology specialist Motive Television (AIM:MTV) has signed a deal to  stream Freeview on tablet computers.

Tags: Technology

Quindell wins Zurich Canada contract 08/04/2014

Insurance services outsourcing specialist Quindell (AIM:QPP) has won a contract with Zurich Canada.

Tags: Canada, Contract wins

Falkland pushing ahead 08/04/2014

Business group Falkland Islands Holdings (AIM:FIH) reported on a strong second half.

Tags: Falklands, Support services

ITM wins £2.8m refuelling deal 03/04/2014

Clean fuel specialist ITM Power (AIM:ITM) has won a deal to supply three refuelling stations in London.

Tags: Clean energy, Contract wins

NetDimensions grabs Uster deal 03/04/2014

Software seller NetDimensions (AIM:NETD) has won a contract with Switzerland-based textile specialist Uster Technologies.

More News